Eureka Equity Partners announced the recapitalization of BlueprintNYC in partnership with Blueprint’s founders and senior team leaders.
Blueprint is a leading healthcare engagement agency that provides meeting and event production, training, experiential marketing, and strategic communications services to innovative pharmaceutical manufacturers and biotech companies. Founded in 2012 and headquartered in New York City, Blueprint offers an integrated suite of promotional services to its clients, with a focus on clients’ sales & marketing teams, that are designed to create internal stakeholder alignment and engagement and to provide mission critical information and training to support the commercialization and marketing of pharmaceutical products.
“Blueprint has built a reputation for superior quality and creativity and sophisticated technical capabilities, which has led to long-standing relationships with its blue-chip customers,” said Eureka Partner Chris Miller, who joined Blueprint’s Board at the close of the transaction. “Eureka has significant experience investing in pharmaceutical services, and we are excited to partner with Blueprint’s founders DJ Hanson and John Sideris as Blueprint enters the next phase of its growth.” Dan Black, a Principal with Eureka who is also on Blueprint’s Board, added, “Outsourced pharmaceutical services is a large and growing market, and Blueprint is well-positioned to continue its impressive growth as it expands its suite of service offerings and broadens its role as an invaluable resource to its customers.”
Blueprint co-Founder DJ Hanson said, “From our first meeting with the Eureka team, we knew they were the right partners for us. They certainly recognized our growth as a company, but they fully understood it was our people and our culture that is what’s behind that success.” Co-Founder John Sideris added, “Blueprint was already poised for incredible growth. We can’t wait to leverage Eureka’s resources and expertise to help take us to a whole new level.”
Webster Bank provided debt facilities to support the acquisition, and Fairmount Partners provided investment banking advisory services to Blueprint to facilitate the transaction.
About Eureka Equity Partners
Eureka Equity Partners is a private equity firm targeting niche market leaders with up to $100 million in revenue across industry segments in which Eureka brings significant experience and operating resources, including business services, health care services, specialty industrials and consumer products. Eureka focuses on partnering with proven managers to drive the growth of promising companies into outstanding enterprises. Eureka leads buyouts that bring significant ownership to the operators driving the success of the business. With this core principle that aligns the interests of our operators and our investors, Eureka is also experienced and comfortable effecting minority recapitalizations with flexible investment structures designed to uniquely meet the needs of the company, its management team and other shareholders. More information about Eureka Equity Partners can be found at www.eurekaequity.com.
About Fairmount Partners
Fairmount Partners (www.fairmountpartners.com) is an independent merger and acquisition advisory firm focused on emerging growth and middle-market companies. Fairmount helps its clients complete mergers and acquisitions, raise funds for growth, acquisitions and liquidity, and design and improve their corporate development strategies. Fairmount’s clients include successful entrepreneurs, private equity-sponsored enterprises, and global public companies. Fairmount’s Pharma Services Group has completed more than 170 transactions for clients that provide services and supplies to the pharmaceutical and medical device sectors in 23 countries throughout North and South America, Europe, Asia and Australia.
